• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Meridian Bioscience dives on “disappointing” Q4 results

Meridian Bioscience dives on “disappointing” Q4 results

November 11, 2010 By MedCity News

MedCity News logo

Diagnostics maker Meridian Bioscience Inc. (NSDQ:VIVO) capped a “disappointing” fiscal 2010 with fourth-quarter profits that fell below Wall Street’s expectations and sent its shares tumbling.

Fourth-quarter profits fell 40 percent to $5.3 million, or 13 cents per diluted share. Excluding special items associated with the costs of an acquisition, per-share earnings came in at 15 cents, according to a statement from the Cincinnati-based company.

Either way you look at it, Meridian’s earnings fell short of analysts’ expectations of 18 cents per share. The disappointing earnings sent the company’s share price down about 5 percent to $22.64 in late-morning trading today. However, the company’s shares rose about 3 percent Wednesday and still are trading fairly close to their 52-week high of $24.12.

For the full year, earnings dropped 19 percent to $27 million, while sales were down 4 percent to $143 million. Fourth-quarter sales fell 16 percent to $36 million.

CEO John Kraeutler labeled the results “disappointing” and blamed the declines on a weak flu season and multiple new competitors in its traditional C. difficile test business. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon.

Taking its testing technology the next step, Meridian launched its Illumigene C. difficile molecular test during the quarter. The Illumigene test can detect the presence of the bacteria in a sample and deliver results within an hour, according to the company. Meridian hopes the molecular test re-energizes its C. difficile product line, as well as provides a platform for other molecular tests.

Still, the company called its financial situation “sound” with $38 million in cash and short-term investments on its balance sheet. Meridian reaffirmed its guidance of earnings between 77 cents and 82 cents per share, and $165 million to $170 million in sales for fiscal 2011.

The company is pinning its 2011 hopes on its C. difficile business, plus its HpSA tests that help to diagnose stomach ulcers and its tests for food-borne illnesses such as E. coli. It also has reduced its expectations for influenza tests in 2011, according to the statement.

Filed Under: Business/Financial News, Diagnostics, MassDevice Earnings Roundup, News Well Tagged With: Meridian Bioscience Inc.

More recent news

  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech
  • GE HealthCare launches new MRI scanner
  • HistoSonics earns first major reimbursement win for non-invasive histotripsy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy